We are excited to be attending the 2025 @US_HAEA National Summit in Baltimore and looking forward to connecting with the #HAE community.

We are excited to announce that Babar Ghias joins BioCryst as our new Chief Financial Officer and Head of Corporate Development.

Today we announced the sale of our European business to Neopharmed Gentili. Read more:

We presented new data at the European Academy of Allergy and Clinical Immunology (@EAACI_HQ) Congress 2025: #EAACI2025

We are looking forward to connecting with the #HAE community and presenting new data at the European Academy of Allergy and Clinical Immunology (@EAACI_HQ) Congress 2025: #EAACI2025

Today we announced the presentation of new data at the C1-Inhibitor Deficiency & Angioedema Workshop in Budapest.

We presented at the @ISPORorg Patient-Centered Research Summit 2025 this week, sharing real-world evidence.

We're pleased to announce the FDA acceptance of our New Drug Application for our oral prophylactic therapy for patients with hereditary angioedema (#HAE) aged 2 to 11 years.

Today we announced the appointment of healthcare investment banking leader, Steve Frank, to our board of directors. Read more:

Our new US Medical Affairs website will enhance our engagement with the scientific community by providing access to scientific content, covering resources to meet the needs of health care practitioners. If you're a US based healthcare practitioner, click:

We will be presenting at The American Academy of Allergy, Asthma & Immunology's (@AAAAI_org) 2025 Annual Meeting taking place at in San Diego, from February 28 – March 3 #AAAAI25

We’re looking forward to connecting with the #HAE community and those in the allergy and immunology field in at #AAAAI25. @AAAAI_org

Happening now: BioCryst is presenting at #JPM2025. Webcast: #JPMHC25

Mark your calendar – BioCryst will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th at 3:00pm PT/6:00pm ET. Learn more: #JPMHC25

We announced an update that has the potential to provide a better quality of life for #HAE patients in Ireland. Learn more about today’s news:

We're presenting new data tomorrow at the American College of Allergy, Asthma & Immunology's (@ACAAI) 2024 Annual Scientific Meeting. #ACAAI24

Today we announced new real-world evidence that will be presented in a poster session at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024 national meeting in Las Vegas from October 14-17, 2024. @amcporg

We’re looking forward to connecting with the #HAE community and those in the allergy and immunology field at the @ACAAI 2024 Annual Scientific Meeting ( #ACAAI24

Today we announced the enrollment of the first participant in a Phase 1 trial evaluating a potent and selective investigational KLK-5 inhibitor designed to provide best-in-class disease-modifying treatment for people with Netherton syndrome.

We've been awarded a $69M contract to supply the United States Center for the Strategic National Stockpile, the nation’s largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency.